Pubblicazioni

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

2020 - MULTIPLE SCLEROSIS

Fox, E; Lovett-Racke, Ae; Gormley, M; Liu, Y; Petracca, M; Cocozza, S; Shubin, R; Wray, S; Weiss, Ms; Bosco, Ja; Power, Sa; Mok, K; Inglese, M.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study

2019 - MULTIPLE SCLEROSIS

Hagens, Marloes Hj; Burggraaff, Jessica; Kilsdonk, Iris D; Ruggieri, Serena; Collorone, Sara; Cortese, Rosa; Cawley, Niamh; Sbardella, Emilia; Andelova, Michaela; Amann, Michael; Lieb, Johanna M; Pantano, Patrizia; Lissenberg-Witte, Birgit I; Killestein, Joep; Oreja-Guevara, Celia; Wuerfel, Jens; Ciccarelli, Olga; Gasperini, Claudio; Lukas, Carsten; Rovira, Alex; Barkhof, Frederik; Wattjes, Mike P

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ÃÂ²1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)

2016 - MULTIPLE SCLEROSIS

Lanzillo, Roberta; Quarantelli, Mario; Pozzilli, Carlo; Trojano, Maria; Amato, Maria Pia; Marrosu, Maria G.; Francia, Ada; Florio, Ciro; Orefice, Giuseppe; Tedeschi, Gioacchino; Bellantonio, Paolo; Annunziata, Pasquale; Grimaldi, Luigi M.; Comerci, Marco; Brunetti, Arturo; Bonavita, Vincenzo; Alfano, Bruno; Marini, Stefano; Brescia Morra, Vincenzo

Pubblicazioni

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ÃÂ²1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ÃÂ²1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)